Loading…

Lacrimal drainage system stenosis associated with Trastuzumab emtansine (Kadcyla®, T-DM1) administration: a case report

Trastuzumab emtansine (Kadcyla®, T-DM1) is an antibody-drug conjugate used to treat HER2 (human epidermal growth factor receptor 2) overexpressing metastatic breast cancer. In this report, we present the first case of lacrimal drainage system stenosis identified after T-DM1 administration, and its s...

Full description

Saved in:
Bibliographic Details
Published in:BMC cancer 2019-08, Vol.19 (1), p.774-774, Article 774
Main Authors: Kim, Chung Young, Kim, Namju, Choung, Ho-Kyung, In Khwarg, Sang
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c5125-e8f2730b3ec41ea4fb8f1466b870ba2e564e33bd98b429e01f95df0b29c80acc3
cites cdi_FETCH-LOGICAL-c5125-e8f2730b3ec41ea4fb8f1466b870ba2e564e33bd98b429e01f95df0b29c80acc3
container_end_page 774
container_issue 1
container_start_page 774
container_title BMC cancer
container_volume 19
creator Kim, Chung Young
Kim, Namju
Choung, Ho-Kyung
In Khwarg, Sang
description Trastuzumab emtansine (Kadcyla®, T-DM1) is an antibody-drug conjugate used to treat HER2 (human epidermal growth factor receptor 2) overexpressing metastatic breast cancer. In this report, we present the first case of lacrimal drainage system stenosis identified after T-DM1 administration, and its successful treatment with a topical steroid. A 36-year-old female with metastatic breast cancer was referred for excessive tearing of both eyes. She previously underwent mastectomy and was treated with multiple anti-cancer regimens. However, metastases to liver and bone were identified and T-DM1 was administered. After 2 months, epiphora developed in both eyes and the patient was referred for ophthalmologic examination. The height of the tear meniscus was increased. The fluorescein dye disappearance test (FDDT) showed a delayed clearance in both eyes. Diagnostic lacrimal probing demonstrated a lower distal canalicular stenosis in both eyes. Dacryocystography indicated multiple focal narrowing of nasolacrimal duct in the right eye and diffused narrowing of nasolacrimal duct in the left eye. Topical eyedrop of tobramycin 0.3% and dexamethasone 0.1% were prescribed four times a day. After 2 months of treatment, the patient reported relief from epiphora, and the height of tear meniscus was normalized in both eyes. T-DM1 administration in breast cancer treatment can induce lacrimal drainage system stenosis, which can be treated effectively with a topical steroid.
doi_str_mv 10.1186/s12885-019-5986-5
format article
fullrecord <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_7d52fcd6b20747418ca1d38373e89cec</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A596594246</galeid><doaj_id>oai_doaj_org_article_7d52fcd6b20747418ca1d38373e89cec</doaj_id><sourcerecordid>A596594246</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5125-e8f2730b3ec41ea4fb8f1466b870ba2e564e33bd98b429e01f95df0b29c80acc3</originalsourceid><addsrcrecordid>eNptku2K1DAUhoso7rp6Af6RgCC7YNd8NG3qD2FZvwZHBB1_h9P0dCZL24xJqjtelBfhldk66zIFCSTh5HlfcpI3SR4zes6Yyl8ExpWSKWVlKkuVp_JOcsyygqU8o8Xdg_1R8iCEK0pZoai6nxwJJlQhJT9OrpdgvO2gJbUH28MaSdiFiB0Zp94FGwiE4IyFiDX5YeOGrDyEOPwcOqgIdhH6YHskpx-gNrsWfv96Tlbp64_sjEDd2d6G6CFa178kQAwEJB63zseHyb0G2oCPbtaT5OvbN6vL9-ny07vF5cUyNZJxmaJqeCFoJdBkDCFrKtWwLM8rVdAKOMo8QyGqulRVxkukrCll3dCKl0ZRMEacJIu9b-3gSm-nXv1OO7D6b8H5tQYfrWlRF7XkjanzitMiKzKmDLBaKFEIVKXByevV3ms7VB3WBvuxt3ZmOj_p7Uav3Xed50pIqUaD0xsD774NGKLubDDYttCjG4LmPC8zyoXMR_TpHl3DeDXbN250NBOuL2SZyzLj2USd_4caR42dNa7Hxo71meBsJhiZiNdxDUMIevHl85x9dsBuENq4Ca4dpt8Mc5DtQeNdCB6b2ydhVE9J1fuk6jGpekqqlqPmyeFb3ir-RVP8Abwh4_A</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2269402356</pqid></control><display><type>article</type><title>Lacrimal drainage system stenosis associated with Trastuzumab emtansine (Kadcyla®, T-DM1) administration: a case report</title><source>Publicly Available Content (ProQuest)</source><source>PubMed Central</source><creator>Kim, Chung Young ; Kim, Namju ; Choung, Ho-Kyung ; In Khwarg, Sang</creator><creatorcontrib>Kim, Chung Young ; Kim, Namju ; Choung, Ho-Kyung ; In Khwarg, Sang</creatorcontrib><description>Trastuzumab emtansine (Kadcyla®, T-DM1) is an antibody-drug conjugate used to treat HER2 (human epidermal growth factor receptor 2) overexpressing metastatic breast cancer. In this report, we present the first case of lacrimal drainage system stenosis identified after T-DM1 administration, and its successful treatment with a topical steroid. A 36-year-old female with metastatic breast cancer was referred for excessive tearing of both eyes. She previously underwent mastectomy and was treated with multiple anti-cancer regimens. However, metastases to liver and bone were identified and T-DM1 was administered. After 2 months, epiphora developed in both eyes and the patient was referred for ophthalmologic examination. The height of the tear meniscus was increased. The fluorescein dye disappearance test (FDDT) showed a delayed clearance in both eyes. Diagnostic lacrimal probing demonstrated a lower distal canalicular stenosis in both eyes. Dacryocystography indicated multiple focal narrowing of nasolacrimal duct in the right eye and diffused narrowing of nasolacrimal duct in the left eye. Topical eyedrop of tobramycin 0.3% and dexamethasone 0.1% were prescribed four times a day. After 2 months of treatment, the patient reported relief from epiphora, and the height of tear meniscus was normalized in both eyes. T-DM1 administration in breast cancer treatment can induce lacrimal drainage system stenosis, which can be treated effectively with a topical steroid.</description><identifier>ISSN: 1471-2407</identifier><identifier>EISSN: 1471-2407</identifier><identifier>DOI: 10.1186/s12885-019-5986-5</identifier><identifier>PMID: 31387552</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Ado-Trastuzumab Emtansine - administration &amp; dosage ; Ado-Trastuzumab Emtansine - adverse effects ; Adult ; Antibacterial agents ; Antibodies ; Antibody-drug conjugates ; Antineoplastic agents ; Antineoplastic Agents, Immunological - administration &amp; dosage ; Antineoplastic Agents, Immunological - adverse effects ; Biological products ; Breast cancer ; Breast Neoplasms - complications ; Breast Neoplasms - diagnosis ; Breast Neoplasms - drug therapy ; Cancer ; Cancer metastasis ; Cancer treatment ; Case Report ; Case studies ; Complications and side effects ; Constriction, Pathologic ; Dexamethasone ; Diagnostic Imaging ; Dosage and administration ; Drug therapy ; Epidermal growth factors ; Epiphora ; Female ; Fluorescein ; Glucocorticoids ; Humans ; Kadcyla ; Lacrimal Apparatus Diseases - diagnosis ; Lacrimal Apparatus Diseases - etiology ; Lapatinib ; Liver ; Liver cancer ; Nasolacrimal duct stenosis ; Patient outcomes ; Stenosis ; Surgery ; Tobramycin ; Tomography, Optical Coherence ; Trastuzumab ; Trastuzumab emtansine</subject><ispartof>BMC cancer, 2019-08, Vol.19 (1), p.774-774, Article 774</ispartof><rights>COPYRIGHT 2019 BioMed Central Ltd.</rights><rights>The Author(s). 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5125-e8f2730b3ec41ea4fb8f1466b870ba2e564e33bd98b429e01f95df0b29c80acc3</citedby><cites>FETCH-LOGICAL-c5125-e8f2730b3ec41ea4fb8f1466b870ba2e564e33bd98b429e01f95df0b29c80acc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6683558/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6683558/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,36990,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31387552$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kim, Chung Young</creatorcontrib><creatorcontrib>Kim, Namju</creatorcontrib><creatorcontrib>Choung, Ho-Kyung</creatorcontrib><creatorcontrib>In Khwarg, Sang</creatorcontrib><title>Lacrimal drainage system stenosis associated with Trastuzumab emtansine (Kadcyla®, T-DM1) administration: a case report</title><title>BMC cancer</title><addtitle>BMC Cancer</addtitle><description>Trastuzumab emtansine (Kadcyla®, T-DM1) is an antibody-drug conjugate used to treat HER2 (human epidermal growth factor receptor 2) overexpressing metastatic breast cancer. In this report, we present the first case of lacrimal drainage system stenosis identified after T-DM1 administration, and its successful treatment with a topical steroid. A 36-year-old female with metastatic breast cancer was referred for excessive tearing of both eyes. She previously underwent mastectomy and was treated with multiple anti-cancer regimens. However, metastases to liver and bone were identified and T-DM1 was administered. After 2 months, epiphora developed in both eyes and the patient was referred for ophthalmologic examination. The height of the tear meniscus was increased. The fluorescein dye disappearance test (FDDT) showed a delayed clearance in both eyes. Diagnostic lacrimal probing demonstrated a lower distal canalicular stenosis in both eyes. Dacryocystography indicated multiple focal narrowing of nasolacrimal duct in the right eye and diffused narrowing of nasolacrimal duct in the left eye. Topical eyedrop of tobramycin 0.3% and dexamethasone 0.1% were prescribed four times a day. After 2 months of treatment, the patient reported relief from epiphora, and the height of tear meniscus was normalized in both eyes. T-DM1 administration in breast cancer treatment can induce lacrimal drainage system stenosis, which can be treated effectively with a topical steroid.</description><subject>Ado-Trastuzumab Emtansine - administration &amp; dosage</subject><subject>Ado-Trastuzumab Emtansine - adverse effects</subject><subject>Adult</subject><subject>Antibacterial agents</subject><subject>Antibodies</subject><subject>Antibody-drug conjugates</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Agents, Immunological - administration &amp; dosage</subject><subject>Antineoplastic Agents, Immunological - adverse effects</subject><subject>Biological products</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - complications</subject><subject>Breast Neoplasms - diagnosis</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Cancer</subject><subject>Cancer metastasis</subject><subject>Cancer treatment</subject><subject>Case Report</subject><subject>Case studies</subject><subject>Complications and side effects</subject><subject>Constriction, Pathologic</subject><subject>Dexamethasone</subject><subject>Diagnostic Imaging</subject><subject>Dosage and administration</subject><subject>Drug therapy</subject><subject>Epidermal growth factors</subject><subject>Epiphora</subject><subject>Female</subject><subject>Fluorescein</subject><subject>Glucocorticoids</subject><subject>Humans</subject><subject>Kadcyla</subject><subject>Lacrimal Apparatus Diseases - diagnosis</subject><subject>Lacrimal Apparatus Diseases - etiology</subject><subject>Lapatinib</subject><subject>Liver</subject><subject>Liver cancer</subject><subject>Nasolacrimal duct stenosis</subject><subject>Patient outcomes</subject><subject>Stenosis</subject><subject>Surgery</subject><subject>Tobramycin</subject><subject>Tomography, Optical Coherence</subject><subject>Trastuzumab</subject><subject>Trastuzumab emtansine</subject><issn>1471-2407</issn><issn>1471-2407</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNptku2K1DAUhoso7rp6Af6RgCC7YNd8NG3qD2FZvwZHBB1_h9P0dCZL24xJqjtelBfhldk66zIFCSTh5HlfcpI3SR4zes6Yyl8ExpWSKWVlKkuVp_JOcsyygqU8o8Xdg_1R8iCEK0pZoai6nxwJJlQhJT9OrpdgvO2gJbUH28MaSdiFiB0Zp94FGwiE4IyFiDX5YeOGrDyEOPwcOqgIdhH6YHskpx-gNrsWfv96Tlbp64_sjEDd2d6G6CFa178kQAwEJB63zseHyb0G2oCPbtaT5OvbN6vL9-ny07vF5cUyNZJxmaJqeCFoJdBkDCFrKtWwLM8rVdAKOMo8QyGqulRVxkukrCll3dCKl0ZRMEacJIu9b-3gSm-nXv1OO7D6b8H5tQYfrWlRF7XkjanzitMiKzKmDLBaKFEIVKXByevV3ms7VB3WBvuxt3ZmOj_p7Uav3Xed50pIqUaD0xsD774NGKLubDDYttCjG4LmPC8zyoXMR_TpHl3DeDXbN250NBOuL2SZyzLj2USd_4caR42dNa7Hxo71meBsJhiZiNdxDUMIevHl85x9dsBuENq4Ca4dpt8Mc5DtQeNdCB6b2ydhVE9J1fuk6jGpekqqlqPmyeFb3ir-RVP8Abwh4_A</recordid><startdate>20190806</startdate><enddate>20190806</enddate><creator>Kim, Chung Young</creator><creator>Kim, Namju</creator><creator>Choung, Ho-Kyung</creator><creator>In Khwarg, Sang</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><general>BMC</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>ISR</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20190806</creationdate><title>Lacrimal drainage system stenosis associated with Trastuzumab emtansine (Kadcyla®, T-DM1) administration: a case report</title><author>Kim, Chung Young ; Kim, Namju ; Choung, Ho-Kyung ; In Khwarg, Sang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5125-e8f2730b3ec41ea4fb8f1466b870ba2e564e33bd98b429e01f95df0b29c80acc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Ado-Trastuzumab Emtansine - administration &amp; dosage</topic><topic>Ado-Trastuzumab Emtansine - adverse effects</topic><topic>Adult</topic><topic>Antibacterial agents</topic><topic>Antibodies</topic><topic>Antibody-drug conjugates</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Agents, Immunological - administration &amp; dosage</topic><topic>Antineoplastic Agents, Immunological - adverse effects</topic><topic>Biological products</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - complications</topic><topic>Breast Neoplasms - diagnosis</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Cancer</topic><topic>Cancer metastasis</topic><topic>Cancer treatment</topic><topic>Case Report</topic><topic>Case studies</topic><topic>Complications and side effects</topic><topic>Constriction, Pathologic</topic><topic>Dexamethasone</topic><topic>Diagnostic Imaging</topic><topic>Dosage and administration</topic><topic>Drug therapy</topic><topic>Epidermal growth factors</topic><topic>Epiphora</topic><topic>Female</topic><topic>Fluorescein</topic><topic>Glucocorticoids</topic><topic>Humans</topic><topic>Kadcyla</topic><topic>Lacrimal Apparatus Diseases - diagnosis</topic><topic>Lacrimal Apparatus Diseases - etiology</topic><topic>Lapatinib</topic><topic>Liver</topic><topic>Liver cancer</topic><topic>Nasolacrimal duct stenosis</topic><topic>Patient outcomes</topic><topic>Stenosis</topic><topic>Surgery</topic><topic>Tobramycin</topic><topic>Tomography, Optical Coherence</topic><topic>Trastuzumab</topic><topic>Trastuzumab emtansine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kim, Chung Young</creatorcontrib><creatorcontrib>Kim, Namju</creatorcontrib><creatorcontrib>Choung, Ho-Kyung</creatorcontrib><creatorcontrib>In Khwarg, Sang</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Science in Context</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>BMC cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kim, Chung Young</au><au>Kim, Namju</au><au>Choung, Ho-Kyung</au><au>In Khwarg, Sang</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Lacrimal drainage system stenosis associated with Trastuzumab emtansine (Kadcyla®, T-DM1) administration: a case report</atitle><jtitle>BMC cancer</jtitle><addtitle>BMC Cancer</addtitle><date>2019-08-06</date><risdate>2019</risdate><volume>19</volume><issue>1</issue><spage>774</spage><epage>774</epage><pages>774-774</pages><artnum>774</artnum><issn>1471-2407</issn><eissn>1471-2407</eissn><abstract>Trastuzumab emtansine (Kadcyla®, T-DM1) is an antibody-drug conjugate used to treat HER2 (human epidermal growth factor receptor 2) overexpressing metastatic breast cancer. In this report, we present the first case of lacrimal drainage system stenosis identified after T-DM1 administration, and its successful treatment with a topical steroid. A 36-year-old female with metastatic breast cancer was referred for excessive tearing of both eyes. She previously underwent mastectomy and was treated with multiple anti-cancer regimens. However, metastases to liver and bone were identified and T-DM1 was administered. After 2 months, epiphora developed in both eyes and the patient was referred for ophthalmologic examination. The height of the tear meniscus was increased. The fluorescein dye disappearance test (FDDT) showed a delayed clearance in both eyes. Diagnostic lacrimal probing demonstrated a lower distal canalicular stenosis in both eyes. Dacryocystography indicated multiple focal narrowing of nasolacrimal duct in the right eye and diffused narrowing of nasolacrimal duct in the left eye. Topical eyedrop of tobramycin 0.3% and dexamethasone 0.1% were prescribed four times a day. After 2 months of treatment, the patient reported relief from epiphora, and the height of tear meniscus was normalized in both eyes. T-DM1 administration in breast cancer treatment can induce lacrimal drainage system stenosis, which can be treated effectively with a topical steroid.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>31387552</pmid><doi>10.1186/s12885-019-5986-5</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1471-2407
ispartof BMC cancer, 2019-08, Vol.19 (1), p.774-774, Article 774
issn 1471-2407
1471-2407
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_7d52fcd6b20747418ca1d38373e89cec
source Publicly Available Content (ProQuest); PubMed Central
subjects Ado-Trastuzumab Emtansine - administration & dosage
Ado-Trastuzumab Emtansine - adverse effects
Adult
Antibacterial agents
Antibodies
Antibody-drug conjugates
Antineoplastic agents
Antineoplastic Agents, Immunological - administration & dosage
Antineoplastic Agents, Immunological - adverse effects
Biological products
Breast cancer
Breast Neoplasms - complications
Breast Neoplasms - diagnosis
Breast Neoplasms - drug therapy
Cancer
Cancer metastasis
Cancer treatment
Case Report
Case studies
Complications and side effects
Constriction, Pathologic
Dexamethasone
Diagnostic Imaging
Dosage and administration
Drug therapy
Epidermal growth factors
Epiphora
Female
Fluorescein
Glucocorticoids
Humans
Kadcyla
Lacrimal Apparatus Diseases - diagnosis
Lacrimal Apparatus Diseases - etiology
Lapatinib
Liver
Liver cancer
Nasolacrimal duct stenosis
Patient outcomes
Stenosis
Surgery
Tobramycin
Tomography, Optical Coherence
Trastuzumab
Trastuzumab emtansine
title Lacrimal drainage system stenosis associated with Trastuzumab emtansine (Kadcyla®, T-DM1) administration: a case report
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T21%3A25%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Lacrimal%20drainage%20system%20stenosis%20associated%20with%20Trastuzumab%20emtansine%20(Kadcyla%C2%AE,%20T-DM1)%20administration:%20a%20case%20report&rft.jtitle=BMC%20cancer&rft.au=Kim,%20Chung%20Young&rft.date=2019-08-06&rft.volume=19&rft.issue=1&rft.spage=774&rft.epage=774&rft.pages=774-774&rft.artnum=774&rft.issn=1471-2407&rft.eissn=1471-2407&rft_id=info:doi/10.1186/s12885-019-5986-5&rft_dat=%3Cgale_doaj_%3EA596594246%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c5125-e8f2730b3ec41ea4fb8f1466b870ba2e564e33bd98b429e01f95df0b29c80acc3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2269402356&rft_id=info:pmid/31387552&rft_galeid=A596594246&rfr_iscdi=true